Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 1;11(5):843.
doi: 10.3390/cells11050843.

Autologous Haematopoietic Stem Cell Transplantation and Systemic Sclerosis: Focus on Interstitial Lung Disease

Gianluca Bagnato  1 , Antonio Giovanni Versace  1 , Daniela La Rosa  1 , Alberta De Gaetano  1 , Egidio Imbalzano  1 , Marianna Chiappalone  1 , Carmelo Ioppolo  1 , William Neal Roberts  2 , Alessandra Bitto  1 , Natasha Irrera  1 , Alessandro Allegra  1 , Giovanni Pioggia  3 , Sebastiano Gangemi  1
Affiliations
Review

Autologous Haematopoietic Stem Cell Transplantation and Systemic Sclerosis: Focus on Interstitial Lung Disease

Gianluca Bagnato et al. Cells. .

Abstract

Autologous hematopoietic stem cells transplantation (AHSCT) has been employed as treatment for severe systemic sclerosis (SSc) with high risk of organ failure. In the last 25 years overall survival and treatment-related mortality have improved, in accordance with a better patient selection and mobilization and conditioning protocols. This review analyzes the evidence from the last 5 years for AHSCT-treated SSc patients, considering in particular the outcomes related to interstitial lung disease. There are increasing data supporting the use of AHSCT in selected patients with rapidly progressive SSc. However, some unmet needs remain, such as an accurate patient selection, pre-transplantation analysis to identify subclinical conditions precluding the transplantation, and the alternatives for post-transplant ILD recurrence.

Keywords: hematopoietic stem cells transplantation; interstitial lung disease; systemic sclerosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Denton C.P., Khanna D. Systemic sclerosis. Lancet. 2017;390:1685–1699. doi: 10.1016/S0140-6736(17)30933-9. - DOI - PubMed
    1. Wollheim F.A. Classification of systemic sclerosis. Visions and reality. Rheumatology. 2005;44:1212–1216. doi: 10.1093/rheumatology/keh671. - DOI - PubMed
    1. Distler O., Allanore Y., Denton C.P., Matucci-Cerinic M., Pope J.E., Hinzmann B., Davies S., de Oliveira Pena J., Khanna D. Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. Rheumatology. 2018;57:813–817. doi: 10.1093/rheumatology/kex504. - DOI - PMC - PubMed
    1. Denton C.P., Wells A.U., Coghlan J.G. Major lung complications of systemic sclerosis. Nat. Rev. Rheumatol. 2018;14:511–527. doi: 10.1038/s41584-018-0062-0. - DOI - PubMed
    1. Elhai M., Meune C., Boubaya M., Avouac J., Hachulla E., Balbir-Gurman A., Riemekasten G., Airo P., Joven B., Vettori S., et al. Mapping and predicting mortality from systemic sclerosis. Ann. Rheum. Dis. 2017;76:1897–1905. doi: 10.1136/annrheumdis-2017-211448. - DOI - PubMed

MeSH terms